---
title: "Enliven Therapeutics Chief Medical Officer Helen Louise Collins Reports Sale of $192,342 in Common Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302615243.md"
description: "Enliven Therapeutics Chief Medical Officer Helen Louise Collins sold 5,000 common shares on October 19, 2026, at $38.4684 per share, totaling $192,342. On the same date, she exercised stock options for 5,000 shares at $2.48 each. Post-transaction, Collins holds 25,000 direct shares and 101,268 stock options."
datetime: "2026-10-21T21:52:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302615243.md)
  - [en](https://longbridge.com/en/news/302615243.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302615243.md)
generator: "portal-rs"
---

# Enliven Therapeutics Chief Medical Officer Helen Louise Collins Reports Sale of $192,342 in Common Shares

-   Enliven Therapeutics Chief Medical Officer Helen Louise Collins sold 5,000 common shares on October 19, 2026. \* The sale price was $38.4684 per share. \* Collins also exercised stock options for 5,000 common shares at $2.48 per share on the same date. \* Following the transactions, she directly held 25,000 common shares and 101,268 stock options. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701247-26-000014), on October 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)

## Related News & Research

- [Enliven Therapeutics Chief Medical Officer Helen Louise Collins reports sale of $234,203.1101 in common shares](https://longbridge.com/en/news/306180389.md)
- [ELVN: Second-line-plus phase III launch is imminent, with a potential early-2029 readout](https://longbridge.com/en/news/305860981.md)
- [Profit Outlook Raised Could Change The Case For Zeta Global Stock](https://longbridge.com/en/news/306379536.md)
- [Wall St Week Ahead-'Black Friday' brings consumer spending into focus for AI-rocked market](https://longbridge.com/en/news/306395310.md)
- [What Veeva Systems Stock AI Training Integration Means For Shareholders](https://longbridge.com/en/news/306379375.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**